Fly News Breaks for January 22, 2020
Jan 22, 2020 | 09:24 EDT
Guggenheim analyst Dana Flanders noted that FDA approval of Tepezza for Thyroid Eye Disease, or TED, came ahead of the March 8 PDUFA date and with a label that is "broad and incredibly clean." The analyst, who views the label as a best-case outcome, notes that it does not include any restrictions of use as it relates to time of TED diagnosis and that there is no black box warning. He also believes Horizon Therapeutics' net price per course of treatment of about $200,000 is modestly above consensus expectations. Flanders maintains a Buy rating on Horizon shares.
News For HZNP From the Last 2 Days
Aug 5, 2021 | 07:52 EDT
BMO Capital analyst Gary Nachman raised the firm's price target on Horizon Therapeutics to $132 from $118 and keeps an Outperform rating on the shares. The company's Q2 result were an "impressive" beat and raise, with the upside driven by Tepeza relaunch following Q1 supply disruption and faster than expected acceleration in demand, the analyst tells investors in a research note. Nachman adds that Horizon's pipeline "remains underappreciated" and is "progressing nicely", which will be highlighted on the company's R&D day.